Skip to main content

Table 3 Comparison of parameters between 52 weeks-remission and 52 weeks-non remission groups at 12 weeks of TCZ therapy

From: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

  DAS CDAI
R NR p R NR p
ROM 278 ± 62.4 348 ± 98.4 0.008** 276 ± 58.0 308 ± 88.4 0.158
CRP 0.150 ± 0.400 1.68 ± 0.150 0.202 0.219 ± 0.765 0.724 ± 2.28 0.329
MMP-3 120 ± 84.7 119 ± 107 0.964 105 ± 47.3 134 ± 113 0.249
TJC 2.6 ± 4.1 4.7 ± 6.6 0.23 1.7 ± 3.6 4.2 ± 5.5 0.082
SJC 1.0 ± 2.2 1.6 ± 2.7 0.505 0.41 ± 0.9 1.8 ± 3.0 0.037*
HAQ 0.500 ± 0.579 0.800 ± 0.806 0.194 0.285 ± 0.338 0.812 ± 0.739 0.004**
  1. TCZ, tocilizumab; ROM, reactive oxygen metabolites; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; TJC, tender joint count; SJC, swollen joint count; HAQ, health assessment questionnaire; DAS, disease activity score; CDAI, clinical disease activity index; R, remission; NR, non-remission. Values are expressed as mean ± SD. Significantly different between remission and non-remission groups, *p < 0.05, **p < 0.01